Pulmozyme (dornase alfa) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

			URGENT	
MEMBER INFORMATION				
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
PATIENT INSURANCE ID NUM	MBER:			
IF YOU ARE NOT THE PATIENT OR THE PRESCR FOLLOWING LINK: PRIMETHERAPEUTICS.COM	/NOPP	OSURE AUTHORIZATION FORM WITH TH	HIS REQUEST WHICH CAN BE FOUND AT THE	
PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):				
PRESCRIBER INFORMATION				
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:		
MEDICATION OR MEDICAL I	DISPENSING INFORMATION			
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
☐ NEW THERAPY	RENEWAL	IF RENEWAL: DATE THE	RAPY INITIATED:	
DURATION OF THERAPY (SPE	CIFIC DATES):			

Continued on next page.



Pulmozyme (dornase alfa) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:		
1. HAS THE PATIENT TRIED ANY OTH	ER MEDICATIONS FOR THIS CONDITION	? YES (if yes, complete below) NO	
MEDICATION/THERAPY (SPECIFY	DURATION OF THERAPY (SPECIFY	RESPONSE/REASON FOR	
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:	
2. LIST DIAGNOSES:		ICD-10:	
☐ Cystic fibrosis (CF)			
□ Other diagnosis:	ICD-10:		
3. REQUIRED CLINICAL INFORMATIO	N: PLEASE PROVIDE ALL RELEVANT CLINIC	CAL INFORMATION TO SUPPORT A	
PRIOR AUTHORIZATION.			
Clinical Information:			
Does the patient have a baseline for	ced vital capacity (FVC) greater than or e	equal to 40%? □ Yes □ No	
Select if the nationt is currently usin	g the following standard therapy treatm	aents:	
1	ntibiotics (e.g., Tobi, Cayston, azithromy		
I	olution, ProAir HFA, Proventil HFA, Maxa	-	
solution/HFA)	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	, reterior, remembran, repenex	
•	, Lipram, Pancrelipase, Digex, Pancreaze	, Zenpep)	
	g., Pulmicort, Symbicort, prednisone)		
Reauthorization:			
If this is a reauthorization request, a	newer the following question:		
_	ve disease response to therapy?* Yes	□ No *Please submit documentation.	
Thus the putient experienced a positi	Te disease response to therapy.		
-		failed, and/or any other information the	
physician feels is important to this re	eview?		
	_		
Please note: Not all drugs/diagnosis	are covered on all plans. This request ma	y be denied unless all required	
information is received.			
ATTESTATION: I attest the information	on provided is true and accurate to the b	est of my knowledge. I understand that	
	up or its designees may perform a routin	•	
information necessary to verify the a	ccuracy of the information reported on the	his form.	
Prescriber Signature or Electronic I.D). Verification:	Date:	
•	ccompanying this transmission contain confidentia		
	ereby notified that any disclosure, copying, distrib		

FAX THIS FORM TO: 800-424-7640

of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX)

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811



and arrange for the return or destruction of these documents.